Divis Laboratories Ltd gains for third consecutive session
NiveshIQ
NSE: DIVISLAB · Pharma
Divi's Laboratories Ltd.
₹7,784.50▲ ₹359.50 (+4.84%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on DIVISLAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Divi's Laboratories Ltd.
Divi's Laboratories Limited is a leading Indian pharmaceutical company that engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals across various international markets. The company's key revenue drivers include the sale of APIs and intermediates, as well as custom synthesis contract manufacturing services. In recent years, Divi's Laboratories has expanded its product portfolio to include a range of carotenoids and vitamins used in the food, beverage, and dietary supplement industries. The company has a strong competitive position in the Indian pharmaceutical market, with a market share of over 20%. Divi's Laboratories has a growth outlook driven by increasing demand for generic APIs and nutraceuticals, as well as its expan
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹7,845 Cr +1.00% | ₹9,360 Cr +19.30% | ₹10,560 Cr +12.80% |
| EBITDA Margin | 28.08% | 31.70% | 37.39% |
| Net Profit | ₹1,600 Cr -12.20% | ₹2,191 Cr +36.90% | ₹2,642 Cr +20.60% |
| EPS | ₹60.28 | ₹82.54 | ₹96.75 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Divis Laboratories Ltd gains for third consecutive session
Divis Laboratories shares rise 2.06 percent to Rs 7,397.50
🔒
+ 3 more stories about Divi's Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹2, 831 Cr, PAT ₹751 Cr, EPS ₹28.29, EBITDA margin 38.5%. Growth context: revenue YoY +9.5%, PAT YoY +13.4%, revenue QoQ +8.7%, PAT QoQ +28.8%. Street verdict: inline, revenue surprise -0.8%, PAT surprise +2.6%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹10, 560 Cr, PAT ₹2, 642 Cr, EBITDA margin 37.4%, EPS ₹96.75. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for DIVISLAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track DIVISLAB alongside your other holdings
Unlock full DIVISLAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Divi's Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Divi's Laboratories Ltd. (DIVISLAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Divi's Laboratories Ltd.?
Divi's Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹17,799,668.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.